Browsing by Author "Ozkilic H."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    99mTc-Doxycycline hyclate: A new radiolabeled antibiotic for bacterial infection imaging
    (John Wiley and Sons Ltd, 2014) Ilem-Özdemir D.; Asikoglu M.; Ozkilic H.; Yilmaz F.; Hosgor-Limoncu M.; Ayhan S.
    Radiolabeled antibiotics are promising radiopharmaceuticals for the precise diagnosis and detection of infectious lesions. Doxycycline Hyclate (DOX) was chosen to investigate new 99mTc-labeled antibacterial agent. Ready to use freeze dry kits were formulated with optimum labeling conditions. Human serum stability, sterility, and pyrogenicity of kits were estimated, and gamma scintigraphy, in vivo biodistribution, and histopathological studies with bacterial infected rats were performed. DOX were successfully labeled by 99mTc with high radiochemical purity, and the labeled compound was stable in human serum. Kits were sterile, pyrogen-free, and stable up to 6 months. Static images depicted rapid distribution throughout the body and high uptake in bacterial infected thigh muscle. The uptake ratios of radiopharmaceuticals in infected thigh muscle were found above 2 up to 5 h. Five hours after injection, the rats were sacrificed, and biodistribution was determined. Samples of bacterial infected muscle, healthy muscle, blood, liver, spleen, lung, kidney, stomach, intestine, urine and heart were weighed, and the radioactivity was measured by using a gamma counter. The %ID/g of 99mTc-DOX was found 0.23 ± 0.06 for infected thigh muscle. According to the imaging, biodistribution, and histopathological studies, the promising characteristics of 99mTc-DOX make the new radiopharmaceutical valuable to examine for future studies. Copyright © 2013 John Wiley & Sons, Ltd.
  • No Thumbnail Available
    Item
    Gamma scintigraphy and biodistribution of 99mTc-cefotaxime sodium in preclinical models of bacterial infection and sterile inflammation
    (John Wiley and Sons Ltd, 2016) Ilem-Ozdemir D.; Asikoglu M.; Ozkilic H.; Yilmaz F.; Hosgor-Limoncu M.; Ayhan S.
    99mTc-cefotaxime sodium (99mTc-CEF) was developed and standardized under varying conditions of reducing and antioxidant agent concentration, pH, radioactivity dose, and reducing agent type. Labeling studies were performed by changing the selected parameters one by one, and optimum labeling conditions were determined. After observing the conditions for maximum labeling efficiency and stability, lyophilized freeze dry kits were prepared accordingly. Simple method for radiolabeling of CEF with 99mTc has been developed and standardized. Labeling efficiency of 99mTc-CEF was assessed by both radio thin-layer chromatography and radio high-performance liquid chromatography and found higher than 90%. The labeled compound was found to be stable in saline and human serum up to 24 h. Two different freeze dry kits were developed and evaluated. Based on the data obtained from this study, both products were stable for 6 months with high labeling efficiency. The prepared cold kit was found sterile and pyrogen free. The bacterial infection and sterile inflammation imaging capacity of 99mTc-CEF was evaluated. Based on the in vivo studies, 99mTc-CEF has higher uptake in infected and inflamed thigh muscle than healthy thigh muscle. Cefotaxime sodium (CEF) was successfully labeled with 99mTc from newly developed instant kit. Radiochemical purity was found greater than 90% and the labeled compound was stable in human serum during incubation period up to 24 h. The improved kit was found to be sterile, pyrogen free and stable up to 6 months. According to gamma scintigraphy studies, 99mTc-CEF showed a higher uptake in bacterial infected and sterile inflamed muscle than healthy thigh muscle. © Copyright 2016 John Wiley & Sons, Ltd.